The Journal of Immunology, Vol 157, Issue 1 265-270, Copyright © 1996 by American Association of Immunologists

ARTICLES

T cell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of schistosome-infected mice

A Metwali, D Elliott, AM Blum, J Li, M Sandor and JV Weinstock
Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.

Granulomas form in the liver and intestines of mice infected with the parasite Schistosoma mansoni. Vasoactive intestinal peptide (VIP) is a neurokine that can modulate aspects of the immune response by acting through receptors within the granuloma. Cloned are two novel VIP receptor (VIPR) mRNAs (VIPR1 and VIPR2) that also bind a second neurokine called pituitary adenylated cyclase-activating polypeptide (PACAP). The objective of this study was to determine if granulomas express either VIPR1 or VIPR2. Using a radioligand-binding assay, it was established that PACAP is as effective as VIP at displacing radiolabeled VIP from splenocytes and granuloma cells, and that most if not all VIPRs in the spleen and granulomas bind PACAP. PCR amplification of reverse transcribed RNA determined that granulomas express both VIPR1 and VIPR2 mRNAs. Gel electrophoresis and nucleotide sequencing confirmed the authenticity of the PCR products. Also, both receptor subtypes were amplified from several granuloma CD4+ T cell lines; yet reverse transcribed RNA from T cell-depleted, dispersed granuloma cells had only VIPR1 RNA. It is notable that reverse transcriptase-PCR detected only VIPR1 in the thymus and spleen, which are organs rich in T lymphocytes. Thus, the granulomas and spleens from mice with schistosomiasis contain cells that display authentic VIP/PACAP receptors. Moreover, these data suggest that T cells in different compartments vary in VIPR subtype expression. VIPR1 and VIPR2 may have different physiologic roles in inflammation.

This article has been cited by other articles:

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				A. Metwali, A. M. Blum, D. E. Elliott, and J. V. Weinstock IL-4 inhibits vasoactive intestinal peptide production by macrophages Am J Physiol Gastrointest Liver Physiol, July 1, 2002; 283(1): G115 - G121. [Abstract] [Full Text] [PDF]

				A. METWALI, A. M. BLUM, J. LI, D. E. ELLIOTT, and J. V. WEINSTOCK IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis FASEB J, May 1, 2000; 14(7): 948 - 954. [Abstract] [Full Text]

				N. JABRANE-FERRAT, D. BLOOM, A. WU, L. LI, D. LO, S. P. SREEDHARAN, C. W. TURCK, and A. E. J. GOETZL Enhancement by vasoactive intestinal peptide of {gamma}-interferon production by antigen-stimulated type 1 helper T cells FASEB J, February 1, 1999; 13(2): 347 - 353. [Abstract] [Full Text]

				E. J. GOETZL, R. R. PANKHANIYA, G. O. GAUFO, Y. MU, M. XIA, and S. P. SREEDHARAN Selectivity of Effects of Vasoactive Intestinal Peptide on Macrophages and Lymphocytes in Compartmental Immune Responses Ann. N.Y. Acad. Sci., May 1, 1998; 840(1): 540 - 550. [Abstract] [Full Text] [PDF]

				M. Xia, S. P. Sreedharan, D. R. Bolin, G. O. Gaufo, and E. J. Goetzl Novel Cyclic Peptide Agonist of High Potency and Selectivity for the Type II Vasoactive Intestinal Peptide Receptor J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 629 - 633. [Abstract] [Full Text]